This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg. Active years: 2015.
Company Filing History:
1 out of 159 
1 out of 63 
Years Active: 2015
Title: The Innovative Contributions of Peter Herhaus
Introduction
Peter Herhaus is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of medical research, particularly in the treatment of pancreatic cancer. His innovative work has led to the development of a patent that addresses critical challenges in cancer therapy.
Latest Patents
Peter Herhaus holds a patent for "Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer." This invention focuses on compounds that inhibit CD95 signaling in pancreatic cancer cells. The patent outlines the use of these compounds in medicaments aimed at preventing and treating pancreatic cancer, as well as inhibiting the migration of cancer cells and managing inflammatory reactions. Additionally, the patent describes methods for identifying such compounds and formulating them into effective medicaments.
Career Highlights
Throughout his career, Peter Herhaus has worked with esteemed institutions such as the Deutsches Krebsforschungszentrum and Ruprecht-Karls-Universität Heidelberg. His research has been pivotal in advancing the understanding and treatment of pancreatic cancer, showcasing his dedication to improving patient outcomes.
Collaborations
Peter has collaborated with notable colleagues, including Susanne Kleber and Thilo Welsch. These partnerships have enriched his research and contributed to the success of his innovative projects.
Conclusion
Peter Herhaus exemplifies the spirit of innovation in medical research, particularly in the fight against pancreatic cancer. His contributions through patents and collaborations highlight the importance of continued research and development in this critical area of healthcare.